Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies

Bernhard Lämmle

doi:10.1055/a-1191-7198

Hämostaseologie, Table of Contents

Hamostaseologie 2020; 40(04): 414-419
DOI: 10.1055/a-1191-7198

Review Article

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies^[*]

Authors

Bernhard Lämmle

¹Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

²Center for Thrombosis and Hemostasis, University Medical Center, Johannes Gutenberg University, Mainz, Germany

³Haemostasis Research Unit, University College London, London, United Kingdom

Abstract

Three selected casuistic studies of individual patient problems from my long-standing professional experience are presented. I intend to highlight the potential contribution of case studies, including new approaches of laboratory investigation, for the advancement of pathophysiological knowledge and would encourage to “rehabilitate” the low academic profile generally attributed to “case reports.”

Keywords

bleeding complications - vitamin K antagonist - F9 propeptide mutation - congenital - autoimmune - thrombotic thrombocytopenic purpura - ADAMTS13 - patent ductus arteriosus - case reports

Full Text

References

References
1 Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98 (07) 1619-1625
2 Oldenburg J, Quenzel EM, Harbrecht U. et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98 (01) 240-244
3 Oldenburg J. Current and future prospects in haemostasis [in German]. Hamostaseologie 2006; 26 (01) 13-21
4 Oldenburg J, Kriz K, Wuillemin WA. et al; Study Group on Hereditary Warfarin Sensitivity. Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). Thromb Haemost 2001; 85 (03) 454-457
5 Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?. Br J Haematol 1997; 99 (02) 467-468
6 Upshaw Jr JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978; 298 (24) 1350-1352
7 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
8 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
9 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
10 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89 (09) 3097-3103
11 Lämmle B, von Auer C. History of thrombotic thrombocytopenic purpura and the von Willebrand factor-cleaving protease, ADAMTS13. In: GM Rodgers, ed. ADAMTS13, Biology and Disease. Cham: Springer International Publishing; 2015: 1-19
12 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855): 488-494
13 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
14 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-24
15 Mariotte E, Azoulay E, Galicier L. et al; French Reference Center for Thrombotic Microangiopathies. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016; 3 (05) e237-e245
16 Scully M, Cataland S, Coppo P. et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15 (02) 312-322
17 Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017; 3: 17020
18 Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017; 130 (10) 1181-1188
19 Scully M, Knöbl P, Kentouche K. et al. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood 2017; 130 (19) 2055-2063
20 Masias C, Cataland SR. Novel therapies in thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost 2017; 2 (01) 19-26
21 Scully M, Cataland SR, Peyvandi F. et al; HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380 (04) 335-346
22 Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med 2019; 381 (17) 1653-1662
23 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019; 134 (13) 1095-1105
24 Roose E, Joly BS. Current and future perspectives on ADAMTS13 and thrombotic thrombocytopenic purpura. Hämostaseologie 2020; 40: 322-336
25 Roose E, Schelpe AS, Tellier E. et al. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood 2020; 136 (03) 353-361
26 Fujimura Y, Matsumoto M, Isonishi A. et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl. 01) 283-301
27 Fujimura Y, Lämmle B, Tanabe S. et al. Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome. Blood Adv 2019; 3 (21) 3191-3195
28 Tanabe S, Yagi H, Kimura T. et al. Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses. Int J Hematol 2012; 96 (06) 789-797

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies[*]

Authors

Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies^[*]